Olivia Gardner

1.2k citations

22 papers · 929 indexed · h-index 13

Impact in

Oncology top 10%
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
Molecular Biology
- Melanoma and MAPK Pathways
- Peroxisome Proliferator-Activated Receptors
- PI3K/AKT/mTOR signaling in cancer

Papers in ⓘ

Physiology 4
- Adenosine and Purinergic Signaling 4
Oncology 12
- Cancer Immunotherapy and Biomarkers 6
- Colorectal Cancer Treatments and Studies 3

Co-authors: Lee M. Graves (6 shared papers)Brian J. Dewar (3 shared papers)Ching-Shih Chen (2 shared papers)H. Shelton Earp (2 shared papers)Danièle Ouellet (2 shared papers)James M. Samet (2 shared papers)Douglas J. DeMarini (2 shared papers)Chung-Wai Shiau (1 shared paper)
Journals: Journal of Clinical Oncology (10 papers)Journal of Biological Chemistry (3 papers)Molecular Pharmacology (2 papers)Cancer Research (2 papers)Blood (1 paper)
Partner nations: United States South Korea Canada

In The Last Decade

Olivia Gardner

21 papers receiving 914 citations

Peers

Countries citing papers authored by Olivia Gardner

Since Specialization

Citations

This map shows the geographic impact of Olivia Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivia Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivia Gardner more than expected).

Fields of papers citing papers by Olivia Gardner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivia Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivia Gardner. The network helps show where Olivia Gardner may publish in the future.

Co-authors

The 25 scholars most cited alongside Olivia Gardner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Olivia Gardner Line = papers co-authored together Olivia Gardner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor Journal of Clinical Oncology ·Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis	2012	356
2	Dependence of Peroxisome Proliferator-activated Receptor Ligand-induced Mitogen-activated Protein Kinase Signaling on Epidermal Growth Factor Receptor Transactivation Journal of Biological Chemistry ·Olivia Gardner, Brian J. Dewar, H. Shelton Earp, James M. Samet, Lee M. Graves	2003	94
3	Activation of Mitogen-Activated Protein Kinases by Peroxisome Proliferator-Activated Receptor Ligands: An Example of Nongenomic Signaling Molecular Pharmacology ·Olivia Gardner, Brian J. Dewar, Lee M. Graves	2005	87
4	Peroxisome Proliferator-activated Receptor γ-independent Activation of p38 MAPK by Thiazolidinediones Involves Calcium/Calmodulin-dependent Protein Kinase II and Protein Kinase R Journal of Biological Chemistry ·Olivia Gardner, Chung-Wai Shiau, Ching-Shih Chen, Lee M. Graves	2005	83
5	Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma Cancer Chemotherapy and Pharmacology ·Danièle Ouellet, Nastya Kassir, Joannellyn Chiu, Samer Mouksassi, Cathrine Leonowens, Donna S. Cox, Douglas J. DeMarini, Olivia Gardner, Wendy Crist, Kiran Klaus Patel	2016	42
6	Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study Cancer Immunology Research ·Fiona Simpkins, Aurea E. Flores, Christina Chu, Jonathan S. Berek, Joseph A. Lucci, Sharon C. Murray, John F. Bauman, Herbert Struemper, Fiona Germaschewski, Zdenka Jonak, Olivia Gardner, John Toso, George Coukos	2013	41
7	Auto-inhibition of the Dbl Family Protein Tim by an N-terminal Helical Motif Journal of Biological Chemistry ·Marielle E. Yohe, Kent L. Rossman, Olivia Gardner, Antoine E. Karnoub, Jason T. Snyder, Svetlana Gershburg, Lee M. Graves, Channing J. Der, John Sondek	2007	40
8	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. Journal of Clinical Oncology ·Karen Kelly, Julien Mazières, Natasha B. Leighl, Fabrice Barlési, Gérard Zalcman, Michael S. Gordon, Karen L. Reckamp, David R. Gandara, Carlos Gomez‐Roca, Jaafar Bennouna, Byoung Chul Cho, Keunchil Park, Jeffrey R. Infante, Donald Richards, Yuehui Wu, Daniel Schramek, Donna S. Cox, Olivia Gardner, Vijay Gopal Reddy Peddareddigari, George R. Blumenschein	2013	36
9	A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination With Rituximab in Patients With Non-Hodgkin Lymphoma Journal of Immunotherapy ·Michael J. Robertson, Justin Kline, Herbert Struemper, Kevin M. Koch, John W. Bauman, Olivia Gardner, Sharon C. Murray, Fiona Germaschewski, Jill Weisenbach, Zdenka Jonak, John Toso	2013	29
10	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. Journal of Clinical Oncology ·David R. Gandara, Sandrine Hiret, George R. Blumenschein, Fabrice Barlési, Jean‐Pierre Delord, J. Madelaine, Jeffrey R. Infante, Karen L. Reckamp, Primo N. Lara, Christine Audebert, Byoung Chul Cho, Keunchil Park, Fadi S. Braiteh, Robert M. Jotte, Yuehui Wu, Daniel Schramek, Alexandra M. Piepszak, Olivia Gardner, Vijay Gopal Reddy Peddareddigari, Natasha B. Leighl	2013	23
11	Capacitative Calcium Entry Contributes to the Differential Transactivation of the Epidermal Growth Factor Receptor in Response to Thiazolidinediones Molecular Pharmacology ·Brian J. Dewar, Olivia Gardner, Ching-Shih Chen, H. Shelton Earp, James M. Samet, Lee M. Graves	2007	21
12	Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results with cyclophosphamide (Cy) ± fludarabine (Flu) lymphodepletion (LD). Journal of Clinical Oncology ·Carlos Becerra, Gulam A. Manji, Dae Won Kim, Olivia Gardner, Aditya Malankar, Joanne Shaw, Devin Blass, Xiaohui Yi, Aaron E. Foster, Paul Woodard	2019	20
13	Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results from a dose escalation. Journal of Clinical Oncology ·Carlos Becerra, Pamela Hoof, Andrew Scott Paulson, Gulam A. Manji, Olivia Gardner, Aditya Malankar, Joanne Shaw, Devin Blass, Brandon Ballard, Xiaohui Yi, Madhavi Anumula, Aaron E. Foster, Joseph Senesac, Paul Woodard	2019	12
14	ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Sumit K. Subudhi, Johanna C. Bendell, Michael A. Carducci, Lisa M. Kopp, Jennifer L. Scott, Michele M Grady, Olivia Gardner, David R. Wise	2021	11
15	A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors. Journal of Clinical Oncology ·Carlos Becerra, Jeffrey R. Infante, Lawrence Garbo, Michael S. Gordon, David A. Smith, Fadi S. Braiteh, David R. Gandara, Robert M. Jotte, Karen L. Reckamp, Filip Jankú, Howard A. Burris, Kevin M. Bellew, Olivia Gardner, Li Liu, Donna S. Cox, Vijay Gopal Reddy Peddareddigari, George R. Blumenschein	2012	10
16	ARC-4 study: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC). Journal of Clinical Oncology ·Alexander I. Spira, Paul Conkling, Melissa L. Johnson, Olivia Gardner, Houston Gilbert, Michael Scharville, F Yin, Kartik Krishnan, Melissa Paoloni, Arvind Chaudhry	2020	9
17	A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Journal of Clinical Oncology ·Fiona Simpkins, Aurea M. Flores, Christina Chu, Joseph A. Lucci, Jonathan S. Berek, George Coukos, John W. Bauman, Sharon C. Murray, Herbert Struemper, Fiona Germaschewski, Zdenka Jonak, Olivia Gardner, John Toso	2012	5
18	Abstract PS12-12: Efficacy and safety of AB928 plus pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participants with metastatic ovarian and triple negative breast cancer Cancer Research ·Jasgit C. Sachdev, Amy Prawira, Arvind Chaudhry, Vinod Ganju, Caroline Trudeau, Jennifer L. Scott, Rachel Woloski, Melissa Paoloni, Halle Zhang, Olivia Gardner	2021	4
19	A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology ·David R. Wise, Olivia Gardner, Houston Gilbert, Aimee Rieger, Melissa Paoloni, Kartik Krishnan	2020	4
20	Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma, Blood ·Michael J. Robertson, John W. Bauman, Olivia Gardner, Zdenka Jonak, Herbert Struemper, Fiona Germaschewski, Kevin Koch, Sharon C. Murray, Jill Weisenbach, John Toso	2011	1

About Olivia Gardner

Olivia Gardner is a scholar working on Physiology, Oncology, Immunology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 929 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Adenosine and Purinergic Signaling (4 papers), Peroxisome Proliferator-Activated Receptors (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Melanoma and MAPK Pathways (3 papers), Retinoids in leukemia and cellular processes (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). The work is most often cited by research in Oncology (407 citations), Molecular Biology (669 citations), Cancer Research (102 citations), Immunology (136 citations) and Cell Biology (78 citations). Olivia Gardner has collaborated with scholars based in United States, South Korea and Canada. Frequent co-authors include Lee M. Graves, Brian J. Dewar, Ching-Shih Chen, H. Shelton Earp, Danièle Ouellet, James M. Samet, Douglas J. DeMarini, Chung-Wai Shiau, Jeffrey R. Infante and Patrick Hwu. Their work appears in journals such as Journal of Clinical Oncology, Journal of Biological Chemistry, Molecular Pharmacology, Cancer Research and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact